News Content
### Core Conclusion: Monotherapy Demonstrates Clinical Value
https://www.fiercerawsource.com/peptides/premium-high-purity-peptides-cagrilintide.html
Subgroup data from the REDEFINE 1 study presented by Novo Nordisk at the 2025 EASD Congress showed that once-weekly 2.4 mg canagliptin monotherapy, combined with lifestyle interventions, was effective in obese or overweight adults with comorbidities but no diabetes. Even without considering treatment adherence, a mean weight loss of 11.5% was achieved after 68 weeks, significantly better than the 3.0% achieved with placebo.
### Monotherapy Efficacy and Mechanism Highlights
Its mechanism of action differs from GLP-1 inhibitors. By mimicking amylin to activate AMYR/CTR receptors, it directly regulates central appetite signals, reducing food intake and delaying gastric emptying. In clinical trials, 31.6% of participants experienced weight loss exceeding 15% after monotherapy, with improvements in serum triglycerides and fasting blood glucose levels, achieving multiple metabolic benefits.
### Safety as a Key Advantage The monotherapy demonstrated excellent tolerability, with the most common gastrointestinal reactions being mild to moderate and transient. The permanent discontinuation rate due to nausea was only 1.0%, significantly lower than similar weight-loss drugs. This good safety profile ensures long-term adherence and makes it an alternative for patients intolerant to GLP-1 inhibitors.
### Application Prospects and Industry Positioning Novo Nordisk has initiated a dedicated Phase III RENEW study to further expand its application in a broader obese population. As a representative drug for the reactivation of the amylin target, canagliflozin monotherapy, while achieving slightly lower weight loss than smegglutide, still holds a significant position in the multi-billion dollar weight-loss market due to its unique mechanism and safety advantages, making it particularly suitable for patients seeking a balance between efficacy and tolerability.

